RNAZ Latest Press Releases

-- June 8, 2026 --

TransCode Therapeutics to Host R&D Webcast on June 18, 2026 PRNewswire 8:04 AM

-- June 3, 2026 --

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer PRNewswire 8:04 AM

-- May 27, 2026 --

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer PRNewswire 8:04 AM

-- April 27, 2026 --

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University PRNewswire 8:02 AM

-- April 7, 2026 --

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 PRNewswire 8:30 AM

-- March 3, 2026 --

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients PRNewswire 8:01 AM

-- February 23, 2026 --

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development PRNewswire 8:01 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software